Bio-Techne Corporation

NASDAQ:TECH

Biotechnology

Healthcare
$72.75 -1.84%

-$1.03 today

Market cap
$11.43B
Beta
1.36
P/E (TTM)
78.3
EPS (TTM)
$0.70
Dividend yield
0.58%
52W Low $43.20High $72.16

Volume 2.63M

Average 2.66M

TECH Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Bio-Techne CorporationNASDAQ: TECH

Stock-Based Compensation · Q1 FY2027 · quarter ended Sep 2026

Stock-based compensation grows, but more slowly than its trailing trend

Q1 FY2027 stock-based compensation of $13.41M rose 14.8% year over year, behind the +56.0% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 156.3% from the prior quarter. Over 3 fiscal years it compounded at +1.8% a year.

Context

  • Stock-based compensation amounted to 3.4% of revenue in FY2026, unchanged from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +14.8% toward the trailing-twelve-month pace of +56.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$13.41M+156.3% QoQ
Last fiscal yearJun 2026
$41.37M+1.3% YoY
LTMSep 2026
$43.09M+56.0% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+14.8%——
1 year+1.3%——
3-year CAGR+1.8%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2026
41.37M USD
Year-over-year change
+1.3%
4-year CAGR
-0.5%

Stock-Based Compensation vs competitors

How TECH compares with its peers on the latest reported figures

  • TECH's LTM Sep 2026 stock-based compensation of $43.09M is the 6th largest of the 11 companies compared; the peer median is $41.38M.
  • Its year-over-year change of +56.0% is the highest of 9, against a peer median of -17.2%.
  • Stock-based compensation amounts to 3.5% of revenue for TECH, versus a peer median of 1.8%.
TECH Competitors Peer median
Stock-Based Compensation for TECH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DHRDanaher CorporationLTM Sep 2026$297M +1.7%+0.3%1.2%
AAgilent Technologies, Inc.LTM Jul 2026$131M +2.3%+0.8%1.8%
TXG10x Genomics, Inc.LTM Jun 2026$98.74M -20.9%-7.3%16.0%
TMOThermo Fisher Scientific Inc.LTM Sep 2026$84M —+0.3%0.2%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$45.8M +43.1%-1.6%1.8%
TECHBio-Techne CorporationLTM Sep 2026$43.09M +56.0%+1.8%3.5%
QGENQiagen N.V.LTM Jun 2026$36.96M -13.6%+0.6%1.8%
RVTYRevvity, Inc.LTM Jul 2026$24.43M -27.0%-23.7%0.8%
SEERSeer, Inc.LTM Mar 2026$12.88M -49.1%-22.9%85.6%
ALMRAlamar Biosciences, Inc.FY2025$2.87M ——3.9%
BRKRBruker CorporationLTM Jun 2026$0 -100.0%-10.0%0.0%
Peer median (excluding TECH) $41.38M-17.2%-1.6%1.8%

Competitors are the stored peer set for TECH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
FY2026
Jun 2026
Net Income263.1M285.44M168.07M73.4M181.86M
Depreciation & Amortization101.07M107.24M111.71M109.9M97.36M
Deferred Income Tax6.82M(29.57M)(39.45M)(51.11M)13.2M
Stock-Based Compensation42.18M39.23M38.04M40.83M41.37M
Change in Working Capital(69.52M)(90.58M)(10.11M)11.54M(41.3M)
Accounts Receivables(57.6M)(23.36M)(31.13M)42.6M(10.79M)
Inventory(32.01M)(30.17M)(14.22M)(18.14M)(8.23M)
Accounts Payables12.74M(7.91M)25.77M(13.95M)3.18M
Other Working Capital7.35M(29.14M)9.47M1.04M(25.46M)
Other Non-Cash Items(18.38M)(57.37M)30.71M102.99M(406K)
Operating Cash Flow325.27M254.39M298.98M287.56M292.07M
Capital Expenditures(44.91M)(38.24M)(62.88M)(31.01M)(28.85M)
Acquisitions (Net)0(83.36M)(169.71M)(15M)4.62M
Purchases of Investments(25M)(20.5M)(5.53M)(5.53M)0
Sales of Investments26.06M108.46M28.08M1.09M6.04M
Other Investing Activities(53M)(232M)7M15.26M0
Investing Cash Flow(96.85M)(265.65M)(203.03M)(35.18M)(18.19M)
Debt Repayment(85.5M)94M(31M)27M(146M)
Common Stock Issued000080.62M
Common Stock Repurchased(160.95M)(19.56M)(80.04M)(275.73M)(41.68M)
Dividends Paid(50.19M)(50.29M)(50.42M)(50.39M)(49.92M)
Other Financing Activities53.78M(1.54M)39.06M45.22M(12.14M)
Financing Cash Flow(242.85M)22.62M(122.4M)(253.91M)(169.11M)
Effect of Forex Changes(12.09M)(3.36M)(2.33M)11.93M(2.24M)
Net Change in Cash(26.52M)8M(28.78M)10.4M102.53M
Free Cash Flow280.36M216.15M236.1M256.55M263.22M

Bio-Techne Corporation

NASDAQ:TECH

Intrinsic Alpha fair value

Locked

Current Price

$72.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.